Up-regulation of Bcl-xl by hepatocyte growth factor in human mesothelioma cells involves ETS transcription factors

Xiaobo Cao, James Littlejohn, Charles Rodarte, Lidong Zhang, Benjamin Martino, Philip Rascoe, Kamran Hamid, Daniel Jupiter, W. Roy Smythe

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Bcl-xl and the hepatocyte growth factor (HGF) receptor c-Met are both highly expressed in mesotheliomas, where they protect cells from apoptosis and can confer resistance to conventional therapeutic agents. In our current study, we investigate a model for the transcriptional control of Bcl-xl that involves ETS transcription factors and the HGF/Met axis. In addition, the effects of activated c-Met on the phosphorylation of the ETS family transcriptional factors were examined. The transient expression of ETS-2 and PU.1 cDNAs in mesothelioma cell lines resulted in an increase in the promoter activity of Bcl-xl and consequently in its mRNA and protein expression levels, whereas the transcriptional repressor Tel suppressed Bcl-xl transcription. The activation of the HGF/Met axis led to rapid phosphorylation of ETS family transcription factors in mesothelioma cells through the mitogen-activated protein kinase pathway and via nuclear accumulation of ETS-2 and PU.1. A chromatin immunoprecipitation assay further demonstrated that the activation of c-Met enhanced the binding of ETS transcriptional factors to the Bcl-x promoter. Finally, we determined the Bcl-xl and phosphorylated c-Met expression levels in mesothelioma patient samples; these data suggest a strong correlation between Bcl-xl and phosphorylated c-Met levels. Taken together, these findings support a role for c-Met as an inhibitor of apoptosis and an activator of Bcl-xl.

Original languageEnglish (US)
Pages (from-to)2207-2216
Number of pages10
JournalAmerican Journal of Pathology
Volume175
Issue number5
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Mesothelioma
Transcription Factors
Up-Regulation
Hepatocyte Growth Factor
Phosphorylation
Proto-Oncogene Proteins c-met
Apoptosis
Chromatin Immunoprecipitation
Mitogen-Activated Protein Kinases
Complementary DNA
Cell Line
Messenger RNA
human HGF protein
Proteins
Therapeutics

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Up-regulation of Bcl-xl by hepatocyte growth factor in human mesothelioma cells involves ETS transcription factors. / Cao, Xiaobo; Littlejohn, James; Rodarte, Charles; Zhang, Lidong; Martino, Benjamin; Rascoe, Philip; Hamid, Kamran; Jupiter, Daniel; Smythe, W. Roy.

In: American Journal of Pathology, Vol. 175, No. 5, 2009, p. 2207-2216.

Research output: Contribution to journalArticle

Cao, X, Littlejohn, J, Rodarte, C, Zhang, L, Martino, B, Rascoe, P, Hamid, K, Jupiter, D & Smythe, WR 2009, 'Up-regulation of Bcl-xl by hepatocyte growth factor in human mesothelioma cells involves ETS transcription factors', American Journal of Pathology, vol. 175, no. 5, pp. 2207-2216. https://doi.org/10.2353/ajpath.2009.090070
Cao, Xiaobo ; Littlejohn, James ; Rodarte, Charles ; Zhang, Lidong ; Martino, Benjamin ; Rascoe, Philip ; Hamid, Kamran ; Jupiter, Daniel ; Smythe, W. Roy. / Up-regulation of Bcl-xl by hepatocyte growth factor in human mesothelioma cells involves ETS transcription factors. In: American Journal of Pathology. 2009 ; Vol. 175, No. 5. pp. 2207-2216.
@article{551f04dcb429417eb1a0627e95c2bae3,
title = "Up-regulation of Bcl-xl by hepatocyte growth factor in human mesothelioma cells involves ETS transcription factors",
abstract = "Bcl-xl and the hepatocyte growth factor (HGF) receptor c-Met are both highly expressed in mesotheliomas, where they protect cells from apoptosis and can confer resistance to conventional therapeutic agents. In our current study, we investigate a model for the transcriptional control of Bcl-xl that involves ETS transcription factors and the HGF/Met axis. In addition, the effects of activated c-Met on the phosphorylation of the ETS family transcriptional factors were examined. The transient expression of ETS-2 and PU.1 cDNAs in mesothelioma cell lines resulted in an increase in the promoter activity of Bcl-xl and consequently in its mRNA and protein expression levels, whereas the transcriptional repressor Tel suppressed Bcl-xl transcription. The activation of the HGF/Met axis led to rapid phosphorylation of ETS family transcription factors in mesothelioma cells through the mitogen-activated protein kinase pathway and via nuclear accumulation of ETS-2 and PU.1. A chromatin immunoprecipitation assay further demonstrated that the activation of c-Met enhanced the binding of ETS transcriptional factors to the Bcl-x promoter. Finally, we determined the Bcl-xl and phosphorylated c-Met expression levels in mesothelioma patient samples; these data suggest a strong correlation between Bcl-xl and phosphorylated c-Met levels. Taken together, these findings support a role for c-Met as an inhibitor of apoptosis and an activator of Bcl-xl.",
author = "Xiaobo Cao and James Littlejohn and Charles Rodarte and Lidong Zhang and Benjamin Martino and Philip Rascoe and Kamran Hamid and Daniel Jupiter and Smythe, {W. Roy}",
year = "2009",
doi = "10.2353/ajpath.2009.090070",
language = "English (US)",
volume = "175",
pages = "2207--2216",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Up-regulation of Bcl-xl by hepatocyte growth factor in human mesothelioma cells involves ETS transcription factors

AU - Cao, Xiaobo

AU - Littlejohn, James

AU - Rodarte, Charles

AU - Zhang, Lidong

AU - Martino, Benjamin

AU - Rascoe, Philip

AU - Hamid, Kamran

AU - Jupiter, Daniel

AU - Smythe, W. Roy

PY - 2009

Y1 - 2009

N2 - Bcl-xl and the hepatocyte growth factor (HGF) receptor c-Met are both highly expressed in mesotheliomas, where they protect cells from apoptosis and can confer resistance to conventional therapeutic agents. In our current study, we investigate a model for the transcriptional control of Bcl-xl that involves ETS transcription factors and the HGF/Met axis. In addition, the effects of activated c-Met on the phosphorylation of the ETS family transcriptional factors were examined. The transient expression of ETS-2 and PU.1 cDNAs in mesothelioma cell lines resulted in an increase in the promoter activity of Bcl-xl and consequently in its mRNA and protein expression levels, whereas the transcriptional repressor Tel suppressed Bcl-xl transcription. The activation of the HGF/Met axis led to rapid phosphorylation of ETS family transcription factors in mesothelioma cells through the mitogen-activated protein kinase pathway and via nuclear accumulation of ETS-2 and PU.1. A chromatin immunoprecipitation assay further demonstrated that the activation of c-Met enhanced the binding of ETS transcriptional factors to the Bcl-x promoter. Finally, we determined the Bcl-xl and phosphorylated c-Met expression levels in mesothelioma patient samples; these data suggest a strong correlation between Bcl-xl and phosphorylated c-Met levels. Taken together, these findings support a role for c-Met as an inhibitor of apoptosis and an activator of Bcl-xl.

AB - Bcl-xl and the hepatocyte growth factor (HGF) receptor c-Met are both highly expressed in mesotheliomas, where they protect cells from apoptosis and can confer resistance to conventional therapeutic agents. In our current study, we investigate a model for the transcriptional control of Bcl-xl that involves ETS transcription factors and the HGF/Met axis. In addition, the effects of activated c-Met on the phosphorylation of the ETS family transcriptional factors were examined. The transient expression of ETS-2 and PU.1 cDNAs in mesothelioma cell lines resulted in an increase in the promoter activity of Bcl-xl and consequently in its mRNA and protein expression levels, whereas the transcriptional repressor Tel suppressed Bcl-xl transcription. The activation of the HGF/Met axis led to rapid phosphorylation of ETS family transcription factors in mesothelioma cells through the mitogen-activated protein kinase pathway and via nuclear accumulation of ETS-2 and PU.1. A chromatin immunoprecipitation assay further demonstrated that the activation of c-Met enhanced the binding of ETS transcriptional factors to the Bcl-x promoter. Finally, we determined the Bcl-xl and phosphorylated c-Met expression levels in mesothelioma patient samples; these data suggest a strong correlation between Bcl-xl and phosphorylated c-Met levels. Taken together, these findings support a role for c-Met as an inhibitor of apoptosis and an activator of Bcl-xl.

UR - http://www.scopus.com/inward/record.url?scp=73649086545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73649086545&partnerID=8YFLogxK

U2 - 10.2353/ajpath.2009.090070

DO - 10.2353/ajpath.2009.090070

M3 - Article

C2 - 19834061

AN - SCOPUS:73649086545

VL - 175

SP - 2207

EP - 2216

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 5

ER -